What Did the Research Discover? High blood pressure (hypertension) is a major risk factor for heart disease, stroke, and kidney disease. While experts have developed guidelines to help manage hypertension, recent data show that blood pressure control in the U.S. is getting worse instead of better. From 1999 to 2014, blood pressure control improved, but since then,...
What Did the Research Discover? Researchers studied sacituzumab govitecan (SG) as a possible treatment for advanced endometrial cancer (EC) in patients who had already undergone chemotherapy and immunotherapy. The study was part of the TROPiCS-03 trial, which included patients with various metastatic solid tumors. In this phase II study, 41 patients with advanced EC...
What Did the Research Discover? Researchers investigated whether COVID-19 infection increases the long-term risk of developing autoimmune and autoinflammatory connective tissue disorders. The study included 6,912,427 participants in South Korea, with 3,145,388 individuals who had COVID-19 and 3,767,039 who did not. The participants were followed for at least 180...
For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation...
For Immediate Release: March 07, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Wednesday, the FDA approved Encelto (revakinagene taroretcel-lwey), an allogeneic encapsulated cell-based gene therapy for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). MacTel is a...
For Immediate Release: March 04, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Monday, the FDA approved the first generics of Xarelto (rivaroxaban), 2.5 mg, tablets to reduce the risk of major cardiovascular events in adult patients with coronary artery disease (CAD) and to reduce the risk of...